Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)
The "CAR-T" immunotherapy ("Chimeric Antigen Receptor T cell therapies") is a therapy based on T cells expressing a chemical receptor for a specific antigen indicated for patients with some types of oncohematological pathologies that have not responded to other forms treatment, such as: relapsed or refractory non-Hodgk
| Condition(s) | CAR-T Therapy Complications |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The "CAR-T" immunotherapy ("Chimeric Antigen Receptor T cell therapies") is a therapy based on T cells expressing a chemical receptor for a specific antigen indicated for patients with some types of oncohematological pathologies that have not responded to other forms treatment, such as: relapsed or refractory non-Hodgkin's lymphomas, including diffuse large B-cell lymphoma, primary B-cell mediastinal lymphoma, transformed follicular lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, in children and young adults (\<26 years) and multiple myeloma. This therapy is an absolutely innovative approach which consists of a personalized live cell immunotherapy that modifies the immune system of the recipient patient to make it able to recognize and eradicate the neoplastic cells expressin |
| Who can participate | Inclusion Criteria: Patients aged ≥ 18 years. Patients with haematological pathology admitted to be subjected to CAR-T Therapy at the Advanced Cell Therapy Program, IRCCS University Hospital of Bologna. Patients who consent to participate in this study after signing informed consent. Exclusion Criteria: \- |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Lead sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Locations | Bologna, Italy, Italy |
| Start date | 2021-05-14 |
| NCT ID | NCT04892433 |
| Official listing | https://clinicaltrials.gov/study/NCT04892433 |